Navenibart
Hereditary Angioedema (HAE) Prophylaxis
Phase 2Investigational
Key Facts
Indication
Hereditary Angioedema (HAE) Prophylaxis
Phase
Phase 2
Status
Investigational
Company
About BioCryst Pharmaceuticals
Founded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.
View full company profile